Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis

Summary

The aim of this study was to determine whether patients with coronary artery disease (CAD) and concomitant peripheral arterial disease (PAD) have a greater inflammatory status than those with CAD alone. To this aim, we evaluated PAD (ankle/brachial pressure index <0.9), and measured plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6) and the soluble forms of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in 234 patients who underwent coronary angiography. Median levels of CRP, IL-6 and sICAM-1 were higher in the CAD without PAD (n=134) and CAD+PAD (n=40) groups than in 60 patients without either disease (“controls”). Median CRP values were higher in patients with CAD+PAD than in patients with CAD alone (4.7 mg/L [1.5;7.6] vs 2.4 mg/L [0.9;3.8], p < 0.01). Three-vessel CAD was diagnosed in 60% of CAD+PAD patients and in 21% (p< 0.01) of CAD only patients. After adjustment for confounding factors, only PAD was independently associated with three-vessel CAD (p<0.001). This association was maintained after adjustment for IL-6, the only inflammatory parameter significantly associated with three-vessel CAD at univariate analysis (p<0.01). In conclusion, in CAD the coexistence of PAD is associated with a greater inflammatory status and more widespread coronary atherosclerosis. These results could help to explain the high cardiovascular risk of patients with concomitant CAD and PAD and suggest that PAD be included among the variables used to identify CAD patients for further diagnostic evaluation.

Keywords

Coronary artery disease - peripheral arterial disease - inflammation - adhesion molecules

• References

• 1 Eagle KA, Rihal CS, Foster ED. et al. For the coronary artery surgery study (CASS) Investigators. Long-term survival in patients with coronary artery disease: importance of peripheral arterial disease. J Am Coll Cardiol 1994; 23: 1091-5.
• 2 Ross E. Atherosclerosis. An inflammatory disease. N Engl J Med 1999; 340: 115-26.
• 3 Liuzzo G, Biasucci LM, Gallimore JR. et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
• 4 Biasucci LM, Vitelli A, Liuzzo G. et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-7.
• 5 Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-4.
• 6 Langlois M, Duprez D, Delanghe J. et al. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001; 103: 1863-8.
• 7 Löwe GDO, Fowkes FGR, Dawes J. et al. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-20.
• 8 Brevetti G, Martone VD, de Cristofaro T. et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Throm Haemost 2001; 85: 63-6.
• 9 Blankenberg S, Rupprecht HJ, Bickel C. et al. for the AtheroGene Investigators. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-42.
• 10 Rossi E, Biasucci LM, Citterio F. et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002; 105: 800-3.
• 11 Tataru MC, Heinrich J, Junker R. et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21: 1000-8.
• 12 Erren M, Reinecke H, Junker R. et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-63.
• 13 Rezaie-Majd A, Maca T, Bucek RA. et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9.
• 14 van de Ree MA, Huisman MV, Princen HM. et al. Strong decrease of high sensitivity C-reactive protein with high dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-35.
• 15 Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987; 111: 265-9.
• 16 Schieffer B, Schieffer E, Hilfiker-Kleiner D. et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
• 17 Aviram M. Intervention of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Biochem 1996; 34: 599-608.
• 18 Mayr M, Kiechl S, Willeit J. et al. Infection, immunity, and atherosclerosis. Association to antibodies of Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102: 833-9.
• 19 Monaco C, Crea F, Niccoli G. et al. Auto-antiboides against low density lipoproteins in patients with stable angina, unstable angina, or peripheral vascular disease. Eur Hear J 2001; 22: 1572-7.
• 20 Huber C, Batchelor JR, Fuchs D. et al. Immune response associated production of neopterin: release from macrophages primarily under control of interferon γ. J Exp Med 1984; 160: 310
• 21 Wick G, Shett G, Amberger A. et al. Is atherosclerosis an immunological mediated disease?. Immunol Today 1995; 16: 27-33.
• 22 Falkensammer G, Wick G. Dendritic cells in the intima of arteries of children. J Invest Dermatol 1997; 109: 256
• 23 Mendall M, Patel P, Ballam L. et al. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996; 312: 1061-5.
• 24 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effects of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
• 25 Zwaka TP, Hombach V, Torzensky J. C-reactive protein mediate low density lipoprotein uptake by macrophages, implication for atherosclerosis. Circulation 2001; 103: 1194-7.
• 26 Cermak J, Key NS, Bach RR. et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
• 27 Ridker PM, Cushman MJ, Stampfer MJ. et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
• 28 Koenig W, Sund M, Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
• 29 Syvanne M, Pajunen P, Kahri J. et al. Determinants of the severity and extent of coronary artery disease in patients with type-2 diabetes mellitus and in nondiabetic subjects. Coron Artery Dis 2001; 12: 99-106.
• 30 Papamichael CM, Lekakis JP, Stamatelopoulos KS. et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 2000; 86: 615-8.
• 31 Mori T, Sasaki J, Kawaguchi H. et al. Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J 1995; 129: 234-8.
• 32 Madsen T, Skou HA, Hansen VE. et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol 2001; 88: 1139-42.